Yellow fever vaccine: a successful vaccination of an immunocompromised patient

Gowda, Rame; Cartwright, Katharine; Bremner, J; Green, S. T.

doi:10.1111/j.1600-0609.2004.00218.x

Cited by 43 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For yellow fever regions, they should usually be given a yellow fever vaccine waiver letter stating that the contraindication to vaccination is acceptable to most governments; such letters should bear the stamp of an official, approved yellow fever immunization center. While some less immunosuppressed travelers have tolerated the vaccine, including individuals with a distant history of hematological malignancy, 8,9 complications including death have been reported in immunosuppressed individuals after vaccination 10 and recommendations avoid its use in immunocompromised travelers. 11 The findings of Mikati and colleagues 6 that immunocompetent travelers were more likely to visit regions endemic for yellow fever than immunocompromised travelers (22% vs 11%, p = 0.07) may reflect education steering them away from these zones.…”

Section: Of This Issuementioning

confidence: 97%

Safe Travels! After Cancer Treatment

Kotton¹

2013

J Travel Med

View full text Add to dashboard Cite

Section: Of This Issuementioning

confidence: 97%

Safe Travels! After Cancer Treatment

Kotton¹

2013

J Travel Med

View full text Add to dashboard Cite

“…Use of the live attenuated vaccine should be avoided in immunocompromised hosts [149]. Although a few immunosuppressed travelers have tolerated the vaccine (e.g., those in the early stages of HIV infection or who have a distant history of hematological malignancy [150][151][152]), complications, including death, have been reported [153].…”

Section: Viral Infectionmentioning

confidence: 99%

Zoonoses in Solid-Organ and Hematopoietic Stem Cell Transplant Recipients

Kotton

2007

Clinical Infectious Diseases

139

105

View full text Add to dashboard Cite

Numerous reports exist of the transmission of zoonoses to humans during and after solid-organ and hematopoietic stem cell transplantation. Donor-derived infections of numerous etiologies, including West Nile virus infection, Chagas disease, toxoplasmosis, rabies, lymphocytic choriomeningitis virus infection, and infection due to Brucella species have been reported. Most zoonoses occur as a primary infection after transplantation, and immunocompromised patients are more likely to experience significant morbidity and mortality from these infections. Risks of zoonotic infection in the posttransplantation period could be reduced by patient education. Increased recognition of the risks of zoonoses, as well as the advent of molecular biology-based testing, will potentially augment diagnostic aptitude. Documented zoonotic infection as it affects transplantation will be the primary focus of this review.

show abstract

“…3 YFV should be deferred in persons with a history of cancer or transplant recipients until immune recovery, 4 as suggested by two reports describing the lack of YFV AE in immune-recovered BM recipients. 5,6 Mechanisms for YFV-associated neurotropic and viscerotropic diseases are still not completely elucidated. It is likely that immune response may not contain 17D replication, which usually follows the first vaccine dose.…”

mentioning

confidence: 99%